header logo en

 

10 facts web


Phase Ib and Phase II Studies of

Pembrolizumab (MK-3475) in

Combination for Renal Cell

Carcinoma

 
 
 Last updated: July 05, 2017
 STATUS: Ongoing, not recruiting (not accepting new patients) (per ClinicalTrials.gov/NCT02348008)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

WHAT

is the key question that this trial is attempting to answer?

This phase I/II study is a trial in two stages:

  • In the first stage it will determine the optimal dose of a new treatment (a human monoclonal antibody in combination with an immune-oncological agent).
  • The second stage is evaluating the efficacy and safety of the drug combination administered in stage 1 as compared to the single-agents.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study is ongoing but not recruiting any more – 61 patients are currently expected to participate.

WHERE

is the trial available?

The trial will be available in various cancer centres in the USA.
For a complete list of trial locations, please click here:
pdf Trial Locations MK-3475+Bevacizumab (280 KB)
 

STUDY

DESIGN

What does the study look like?

In phase I there will be one study arm (group), all patients will be assigned bevacizumab (Avastin) in combination with pembrolizumab (Keytruda™, MK-3475).

  • bevacizumab (Avastin) a humanized monoclonal antibody that blocks angiogenesis, already approved for the treatment of metastatic RCC
  • pembrolizumab (Keytruda™) is a fully human monoclonal antibody targeting PD-1
All participants will receive bevacizumab and pembrolizumab intravenously in different dosages on day 1 of each 21-day cycle.
Phase II: Once the right dosage is determined in the phase I trial, all patients will be given the combination of bevacizumab + pembolizumab intravenously on day 1 of each 21-day cycle.

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find an IO clinical trial for my cancer?